Information on the target
Curium announced on August 3, 2026, that it had entered into a definitive agreement to merge with Lantheus Holdings, Inc. (NASDAQ: LNTH) in an all-cash transaction valued at up to approximately $8 billion. Under the terms of the agreement, Lantheus shareholders will receive $102.50 per share in cash at closing, along with contingent value rights (CVRs) of up to $12.00 per share tied to commercial milestones through 2030. This implies a potential maximum consideration of approximately $114.50 per share. The merger aims to combine two of the larger independent radiopharmaceutical businesses, returning Lantheus to private ownership.
Curium, controlled by CapVest Partners LLP, operates over 80 manufacturing sites and serves more than 70 countries with a portfolio of over 45 products. The transaction is designed to create a company that spans the full nuclear medicine value chain, from isotope production and manufacturing to diagnostic imaging and targeted radioligand therapy. This merger represents one of the larger healthcare transactions announced in 2026 and serves as an indicator of current sponsor underwriting trends in specialty pharmaceutical assets.
Industry overview in the target’s specific country
The In-Vivo Diagnostic & Testing Substances industry in the United States has experienced significant growth, driven by advancements in technology and an increasing demand for precise diagnostic solutions. The sector is characterized by a diverse range of products, including radiopharmaceuticals, which are essential for imaging and therapeutic applications. The U.S. market is home to several leading companies that specialize in the development and manufacturing of these substances, contributing to a robust competitive landscape.
In recent years, the regulatory environment has evolved to support innovation in the In-Vivo Diagnostic & Testing Substances industry. The U.S. Food and Drug Administration (FDA) has streamlined approval processes for new diagnostic agents, encouraging companies to invest in research and development. This has led to the introduction of novel radiopharmaceuticals that enhance diagnostic accuracy and patient outcomes, particularly in oncology and cardiology.
Moreover, the increasing prevalence of chronic diseases, coupled with an aging population, has fueled demand for advanced diagnostic solutions. The U.S. healthcare system is increasingly focused on personalized medicine, where diagnostic tests play a crucial role in tailoring treatments to individual patients. This trend is expected to drive further growth in the In-Vivo Diagnostic & Testing Substances market, as healthcare providers seek to improve diagnostic capabilities and treatment efficacy.
As the industry continues to evolve, consolidation among key players is anticipated. Companies are increasingly recognizing the value of integrating manufacturing and distribution capabilities to enhance operational ef…